Fresenius announced an exclusive development agreement with WuXi Biologics giving Fresenius access to up to 37 biosimilar candidates over ten years, potentially expanding its marketed and development portfolio from 29 to 66 molecules. The originator products involved represent more than €370 billion in combined list-price-based sales, but that figure is not a forecast of biosimilar revenue. Fresenius will select individual candidates, pay WuXi on a fee-for-service basis, retain global commercialization rights, and determine manufacturing strategy, including potential use of its wholly owned mAbxience network. Initial development is expected to focus on biosimilars of polatuzumab vedotin and teprotumumab.
FSE
Primary source: Fresenius announcement, November 2
Why it matters strategically
This agreement changes how a major healthcare company can construct a biosimilar pipeline.
Rather than independently developing every molecule, Fresenius gains access to a broad development portfolio while preserving the option to select programs individually.
The model potentially reduces upfront commitment but creates dependencies on external development capabilities, manufacturing technology transfer, regulatory requirements, and the timing of originator patent expirations.
The most consequential issue is whether a large portfolio of development options creates superior risk-adjusted value or encourages capital allocation into markets that may become overcrowded.
